ALN-APP
Alnylam shares positive results from phase 1 trial
July 17, 2023Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …
Latest content
Acumentis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
October 26, 2026
